Russ Cummings

Overview

Russ Cummings has a strong track record as an investor in early stage and high growth companies spanning both the healthcare and technology sectors. Russ was recruited to Innovations in 2006 as Chief Investment Officer to build the investment team and portfolio, whilst also playing a hands on role on the board of Nexeon and Circassia. He was closely involved in the sale of Respivert to Johnson & Johnson, which delivered a 4.7x return on Innovations' investment within 3 years. In 2013 he took over as Chief Executive and, having served on the board of Innovations Group plc for the last 9 years, has developed an intimate knowledge of the business and established relationships with the UK's top Universities.

EDIT